AllianceBernstein
BCAX

AllianceBernstein’s Bicara Therapeutics BCAX Stock Holding History

AllianceBernstein’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$536K Buy
31,830
+2,720
+9% +$46.8K ﹤0.01% 2604
2025
Q4 		$490K Sell
29,110
-11,660
-29% -$199K ﹤0.01% 2668
2025
Q3 		$644K Sell
40,770
-4,790
-11% -$53.6K ﹤0.01% 2549
2025
Q2 		$423K Buy
+45,560
New +$543K ﹤0.01% 2731
2025
Q1 		– Sell
-821,264
Closed -$14.3M – 3238
2024
Q4 		$14.3M Buy
821,264
+113,261
+16% +$2.36M ﹤0.01% 1023
2024
Q3 		$18M Buy
+708,003
New +$18.1M 0.01% 945

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

AllianceBernstein's BCAX Position: Q1 2026 in Review

AllianceBernstein increased its Bicara Therapeutics (BCAX) stake by 9.3% in Q1 2026, buying an estimated $46.8K and bringing the position to 31,830 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #2604.

AllianceBernstein first reported a position in BCAX in Q3 2024 and has held it in 6 quarters since. The position peaked at $18M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • AllianceBernstein held 31,830 shares of Bicara Therapeutics worth $536K as of Q1 2026.
  • AllianceBernstein bought 2,720 Bicara Therapeutics shares in Q1 2026, an estimated $46.8K.
  • Bicara Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2604 holding.
  • AllianceBernstein first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • AllianceBernstein's Bicara Therapeutics position peaked at $18M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.